Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program.


Journal

Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041

Informations de publication

Date de publication:
12 2019
Historique:
received: 20 05 2019
accepted: 13 08 2019
revised: 08 08 2019
pubmed: 21 8 2019
medline: 4 9 2020
entrez: 21 8 2019
Statut: ppublish

Résumé

Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease.

Identifiants

pubmed: 31428936
doi: 10.1007/s00401-019-02062-4
pii: 10.1007/s00401-019-02062-4
pmc: PMC6851045
doi:

Substances chimiques

Biomarkers, Tumor 0
Muscle Proteins 0
RNA, Ribosomal, 28S 0
Methyltransferases EC 2.1.1.-
NSUN5 protein, human EC 2.1.1.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1053-1074

Subventions

Organisme : NIGMS NIH HHS
ID : T32 GM136629
Pays : United States
Organisme : Ministerio de Economía y Competitividad
ID : SAF2014-55000-R
Pays : International
Organisme : NIGMS NIH HHS
ID : T32 GM070421
Pays : United States

Références

Mol Cell. 2011 Nov 18;44(4):660-6
pubmed: 22099312
Science. 2005 Sep 2;309(5740):1508-14
pubmed: 16141058
Cancer Res. 2010 Jul 15;70(14):6026-35
pubmed: 20587522
Nucleic Acids Res. 2012 Jun;40(11):5023-33
pubmed: 22344696
Neuro Oncol. 2013 Aug;15(8):979-80
pubmed: 23757293
Nat Rev Drug Discov. 2013 Dec;12(12):931-47
pubmed: 24287781
Science. 2003 Jan 10;299(5604):259-62
pubmed: 12522253
Nat Rev Cancer. 2017 Apr 24;17(5):332
pubmed: 28436470
Nat Rev Clin Oncol. 2017 Jul;14(7):434-452
pubmed: 28031556
Nat Rev Mol Cell Biol. 2013 Jan;14(1):55-61
pubmed: 23258296
Science. 2016 Jun 17;352(6292):1408-12
pubmed: 27313037
EMBO J. 2014 Sep 17;33(18):2020-39
pubmed: 25063673
Biochim Biophys Acta. 2015 Jul;1849(7):845-60
pubmed: 25464034
Arch Biochem Biophys. 2010 Sep 1;501(1):116-23
pubmed: 20361926
Nat Genet. 1998 May;19(1):32-8
pubmed: 9590285
Nucleic Acids Res. 2013 Oct;41(19):9062-76
pubmed: 23913415
Cancer Cell. 2010 May 18;17(5):510-22
pubmed: 20399149
N Engl J Med. 2000 Nov 9;343(19):1350-4
pubmed: 11070098
Acta Neuropathol. 2018 Apr;135(4):601-615
pubmed: 29368212
Cancer Discov. 2017 Apr;7(4):359-368
pubmed: 28320778
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Genome Res. 2017 Sep;27(9):1589-1596
pubmed: 28684555
N Engl J Med. 2008 Mar 13;358(11):1148-59
pubmed: 18337604
Annu Rev Cell Dev Biol. 2015;31:31-54
pubmed: 26443190
RNA. 2014 Oct;20(10):1632-44
pubmed: 25125595
EMBO J. 2010 Jun 2;29(11):1865-76
pubmed: 20453831
Acc Chem Res. 2015 Oct 20;48(10):2715-23
pubmed: 26444384
CA Cancer J Clin. 2016 Jan-Feb;66(1):75-88
pubmed: 26528881
Nat Rev Neurol. 2014 Feb;10(2):68-70
pubmed: 24419684
Biochim Biophys Acta. 2016 Jan;1859(1):59-70
pubmed: 26541084
Cancer Discov. 2017 Oct;7(10):1069-1087
pubmed: 28923911
Nature. 2008 Dec 18;456(7224):971-5
pubmed: 19011615
Dis Model Mech. 2015 Sep;8(9):1013-26
pubmed: 26398160
Cell. 2018 Jul 12;174(2):498-498.e1
pubmed: 30007421
Nature. 2016 Jun 15;534(7607):335-40
pubmed: 27306184
Nat Rev Genet. 2012 Mar 13;13(4):227-32
pubmed: 22411467
J Natl Cancer Inst. 2010 Jul 7;102(13):932-41
pubmed: 20513808
Nucleic Acids Res. 1999 Jan 1;27(1):196-7
pubmed: 9847178
Invest New Drugs. 2017 Apr;35(2):134-144
pubmed: 27975234
Cancer Res. 2012 Jun 15;72(12):3038-47
pubmed: 22532167
Nature. 2014 Sep 4;513(7516):65-70
pubmed: 25079319
Cell. 2015 Jul 2;162(1):59-71
pubmed: 26095252
Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21188-93
pubmed: 22158988
Nat Commun. 2014 Apr 03;5:3608
pubmed: 24699711
Nat Rev Cancer. 2010 Apr;10(4):254-66
pubmed: 20332778
Curr Opin Oncol. 2016 Jan;28(1):65-71
pubmed: 26599292
Nat Rev Cancer. 2010 Sep;10(9):652-60
pubmed: 20733593
Nat Commun. 2015 Jan 30;6:6158
pubmed: 25635753
Neuro Oncol. 2018 May 18;20(6):848-857
pubmed: 29036412
Mol Cell. 2017 Jul 6;67(1):71-83.e7
pubmed: 28625553
Cell. 2017 Jun 15;169(7):1187-1200
pubmed: 28622506
Science. 2006 May 12;312(5775):902-6
pubmed: 16690864
Cell. 2016 Jul 28;166(3):740-754
pubmed: 27397505

Auteurs

Maxime Janin (M)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Vanessa Ortiz-Barahona (V)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Manuel Castro de Moura (MC)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Anna Martínez-Cardús (A)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Pere Llinàs-Arias (P)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Marta Soler (M)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Daphna Nachmani (D)

Department of Medicine and Pathology, Cancer Research Institute, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Joffrey Pelletier (J)

Molecular Mechanisms and Experimental Therapy in Oncology Program, Metabolism and Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Ulrike Schumann (U)

EMBL-Australia Collaborating Group, Department of Genome Sciences, The John Curtin School of Medical Research, The Australian National University, Garran Road, Acton, ACT, 2601, Australia.

Maria E Calleja-Cervantes (ME)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Sebastian Moran (S)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Sonia Guil (S)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Alberto Bueno-Costa (A)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

David Piñeyro (D)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Montserrat Perez-Salvia (M)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Margalida Rosselló-Tortella (M)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Laia Piqué (L)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Joan J Bech-Serra (JJ)

Proteomics Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

Carolina De La Torre (C)

Proteomics Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.

August Vidal (A)

Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.
Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.

María Martínez-Iniesta (M)

Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.

Juan F Martín-Tejera (JF)

Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.

Alberto Villanueva (A)

Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.

Alexandra Arias (A)

Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.

Isabel Cuartas (I)

Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.

Ana M Aransay (AM)

Centro de Investigación Bimédica en Red de Enfermedades hepáticas y Digestivas (CIBERehd), CIC bioGUNE, 801A Bizkaia Technology Park, 48160, Derio, Spain.

Andres Morales La Madrid (AM)

Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.
Pediatric Neuro-Oncology Unit, Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.

Angel M Carcaboso (AM)

Preclinical Therapeutics and Drug Delivery Research Program, Fundacio Sant Joan de Deu, Barcelona, Catalonia, Spain.

Vicente Santa-Maria (V)

Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.
Pediatric Neuro-Oncology Unit, Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.

Jaume Mora (J)

Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain.

Agustin F Fernandez (AF)

Institute of Oncology of Asturias (IUOPA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), 33011, Oviedo, Spain.

Mario F Fraga (MF)

Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Universidad de Oviedo-Principado de Asturias, Oviedo, Spain.

Iban Aldecoa (I)

Pathology-Brain Bank, Hospital Clínic de Barcelona-CDB-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain.

Leire Pedrosa (L)

Glioma and Neural Stem Cell Group and Translational Genomics and Targeted Therapeutics in Solid Tumors Team, IDIBAPS, Barcelona, Catalonia, Spain.

Francesc Graus (F)

Clinical and Experimental Neuroimmunology, IDIBAPS, Barcelona, Catalonia, Spain.

Noemi Vidal (N)

Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.

Fina Martínez-Soler (F)

Faculty of Medicine and Health Sciences-Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.

Avelina Tortosa (A)

Faculty of Medicine and Health Sciences-Bellvitge, Universitat de Barcelona, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.

Cristina Carrato (C)

Department of Pathology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain.

Carme Balañá (C)

Catalan Institute of Oncology, Hospital Germans Trias i Pujol, 08916, Badalona, Barcelona, Catalonia, Spain.

Matthew W Boudreau (MW)

Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.

Paul J Hergenrother (PJ)

Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.

Peter Kötter (P)

Institute for Molecular Biosciences, Goethe University, Frankfurt, Germany.

Karl-Dieter Entian (KD)

Institute for Molecular Biosciences, Goethe University, Frankfurt, Germany.

Jürgen Hench (J)

Division of Neuropathology, Institute of Medical Genetics and Pathology, University Hospital Basel, 4031, Basel, Switzerland.

Stephan Frank (S)

Division of Neuropathology, Institute of Medical Genetics and Pathology, University Hospital Basel, 4031, Basel, Switzerland.

Sheila Mansouri (S)

Division of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.

Gelareh Zadeh (G)

Division of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.

Pablo D Dans (PD)

Joint IRB-BSC Program on Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), 08028, Barcelona, Catalonia, Spain.

Modesto Orozco (M)

Joint IRB-BSC Program on Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), 08028, Barcelona, Catalonia, Spain.
Department of Biochemistry and Biomedicine, University of Barcelona, 08028, Barcelona, Spain.

George Thomas (G)

Molecular Mechanisms and Experimental Therapy in Oncology Program, Metabolism and Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain.
Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain.
Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati Medical School, Cincinnati, OH, 45267-0508, USA.

Sandra Blanco (S)

CIC bioGUNE, 801A Bizkaia Technology Park, 48160, Derio, Spain.
Molecular Mechanisms Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), University of Salamanca, 37007, Salamanca, Spain.

Joan Seoane (J)

Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.
Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.

Thomas Preiss (T)

EMBL-Australia Collaborating Group, Department of Genome Sciences, The John Curtin School of Medical Research, The Australian National University, Garran Road, Acton, ACT, 2601, Australia.
Victor Chang Cardiac Research Institute, Darlinghurst (Sydney), NSW, 2010, Australia.

Pier Paolo Pandolfi (PP)

Department of Medicine and Pathology, Cancer Research Institute, Beth Israel Deaconess Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Manel Esteller (M)

Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Catalonia, Spain. mesteller@carrerasresearch.org.
Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. mesteller@carrerasresearch.org.
Department of Biochemistry and Biomedicine, University of Barcelona, 08028, Barcelona, Spain. mesteller@carrerasresearch.org.
Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. mesteller@carrerasresearch.org.
Josep Carreras Leukaemia Research Institute (IJC), Ctra de Can Ruti, Camí de les Escoles s/n, 08916, Badalona, Barcelona, Catalonia, Spain. mesteller@carrerasresearch.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH